enGene Therapeutics Inc. (ENGN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
7/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseENGN / S&P -74.60% / 15.20% |
LoseENGN / S&P ENGN unavailable / 15.00% |
WinENGN / S&P 107.94% / 50.40% |
| 2026-Q10/3 |
LoseENGN / S&P -24.58% / -4.33% |
LoseENGN / S&P ENGN unavailable / 11.30% |
LoseENGN / S&P -19.08% / 27.70% |
| 2025-Q41/3 |
WinENGN / S&P 32.21% / 2.65% |
LoseENGN / S&P ENGN unavailable / 9.00% |
LoseENGN / S&P -15.33% / 13.40% |
| 2025-Q31/3 |
WinENGN / S&P 87.64% / 8.12% |
LoseENGN / S&P ENGN unavailable / 4.61% |
LoseENGN / S&P -99.28% / 13.45% |
| 2025-Q20/3 |
LoseENGN / S&P -18.75% / 10.94% |
LoseENGN / S&P ENGN unavailable / 4.83% |
LoseENGN / S&P -99.51% / 10.63% |
| 2025-Q10/3 |
LoseENGN / S&P -32.63% / -4.27% |
LoseENGN / S&P ENGN unavailable / 4.98% |
LoseENGN / S&P -98.90% / 10.57% |
| 2024-Q40/3 |
LoseENGN / S&P 0.76% / 2.41% |
LoseENGN / S&P ENGN unavailable / 5.25% |
LoseENGN / S&P -99.01% / 6.15% |
| 2024-Q30/3 |
LoseENGN / S&P -30.01% / 5.89% |
LoseENGN / S&P ENGN unavailable / 5.89% |
LoseENGN / S&P ENGN unavailable / 6.11% |
| 2024-Q20/3 |
LoseENGN / S&P -44.37% / 4.28% |
LoseENGN / S&P ENGN unavailable / 5.38% |
LoseENGN / S&P ENGN unavailable / 5.12% |
| 2024-Q11/3 |
WinENGN / S&P 83.64% / 10.56% |
LoseENGN / S&P ENGN unavailable / 5.71% |
LoseENGN / S&P ENGN unavailable / 5.59% |
| 2023-Q40/3 |
LoseENGN / S&P -15.78% / 11.69% |
LoseENGN / S&P ENGN unavailable / 6.81% |
LoseENGN / S&P ENGN unavailable / 7.78% |
| 2023-Q31/3 |
WinENGN / S&P 2.14% / -3.27% |
LoseENGN / S&P ENGN unavailable / 7.52% |
LoseENGN / S&P ENGN unavailable / -5.03% |
| 2023-Q20/3 |
LoseENGN / S&P 1.80% / 8.74% |
LoseENGN / S&P ENGN unavailable / 9.50% |
LoseENGN / S&P ENGN unavailable / -8.57% |
| 2023-Q10/3 |
LoseENGN / S&P 2.03% / 7.50% |
LoseENGN / S&P ENGN unavailable / 10.77% |
LoseENGN / S&P ENGN unavailable / -15.69% |
| 2022-Q40/3 |
LoseENGN / S&P 2.28% / 7.56% |
LoseENGN / S&P ENGN unavailable / 11.88% |
LoseENGN / S&P ENGN unavailable / -17.99% |
| 2022-Q31/3 |
WinENGN / S&P 1.00% / -4.88% |
LoseENGN / S&P ENGN unavailable / 13.47% |
LoseENGN / S&P ENGN unavailable / -1.41% |
| 2022-Q21/3 |
WinENGN / S&P 0.30% / -16.10% |
LoseENGN / S&P ENGN unavailable / 13.71% |
LoseENGN / S&P ENGN unavailable / 11.04% |
| 2022-Q10/3 |
LoseENGN / S&P ENGN unavailable / -4.60% |
LoseENGN / S&P ENGN unavailable / 15.97% |
LoseENGN / S&P ENGN unavailable / 42.23% |
| 2021-Q40/3 |
LoseENGN / S&P ENGN unavailable / 11.03% |
LoseENGN / S&P ENGN unavailable / 15.00% |
LoseENGN / S&P ENGN unavailable / 96.40% |
| 2021-Q30/3 |
LoseENGN / S&P ENGN unavailable / 0.58% |
LoseENGN / S&P ENGN unavailable / 10.77% |
LoseENGN / S&P ENGN unavailable / 69.42% |
| 2021-Q20/3 |
LoseENGN / S&P ENGN unavailable / 8.55% |
LoseENGN / S&P ENGN unavailable / 6.58% |
LoseENGN / S&P ENGN unavailable / 51.81% |
| 2021-Q10/3 |
LoseENGN / S&P ENGN unavailable / 6.17% |
LoseENGN / S&P ENGN unavailable / -1.06% |
LoseENGN / S&P ENGN unavailable / 7.39% |
| 2020-Q40/3 |
LoseENGN / S&P ENGN unavailable / 12.15% |
LoseENGN / S&P ENGN unavailable / -3.72% |
LoseENGN / S&P ENGN unavailable / -33.42% |
| 2020-Q30/3 |
LoseENGN / S&P ENGN unavailable / 8.93% |
LoseENGN / S&P ENGN unavailable / -2.04% |
LoseENGN / S&P ENGN unavailable / -27.10% |
| 2020-Q20/3 |
LoseENGN / S&P ENGN unavailable / 20.54% |
LoseENGN / S&P ENGN unavailable / -0.46% |
LoseENGN / S&P ENGN unavailable / -27.11% |
| 2020-Q10/3 |
LoseENGN / S&P ENGN unavailable / -19.60% |
LoseENGN / S&P ENGN unavailable / 3.47% |
LoseENGN / S&P ENGN unavailable / -14.75% |
| 2019-Q40/3 |
LoseENGN / S&P ENGN unavailable / 9.07% |
LoseENGN / S&P ENGN unavailable / 5.36% |
LoseENGN / S&P ENGN unavailable / 2.99% |
| 2019-Q30/3 |
LoseENGN / S&P ENGN unavailable / 1.70% |
LoseENGN / S&P ENGN unavailable / 5.02% |
LoseENGN / S&P ENGN unavailable / 0.21% |
| 2019-Q20/3 |
LoseENGN / S&P ENGN unavailable / 4.30% |
LoseENGN / S&P ENGN unavailable / 6.64% |
LoseENGN / S&P ENGN unavailable / 8.65% |
| 2019-Q10/3 |
LoseENGN / S&P ENGN unavailable / 13.65% |
LoseENGN / S&P ENGN unavailable / 8.12% |
LoseENGN / S&P ENGN unavailable / 14.29% |
| 2018-Q40/3 |
LoseENGN / S&P ENGN unavailable / -13.52% |
LoseENGN / S&P ENGN unavailable / 9.05% |
LoseENGN / S&P ENGN unavailable / 18.23% |
| 2018-Q30/3 |
LoseENGN / S&P ENGN unavailable / 7.71% |
LoseENGN / S&P ENGN unavailable / 10.21% |
LoseENGN / S&P ENGN unavailable / 19.06% |
| 2018-Q20/3 |
LoseENGN / S&P ENGN unavailable / 3.43% |
LoseENGN / S&P ENGN unavailable / 9.03% |
LoseENGN / S&P ENGN unavailable / 14.46% |
| 2018-Q10/3 |
LoseENGN / S&P ENGN unavailable / -0.76% |
LoseENGN / S&P ENGN unavailable / 7.68% |
LoseENGN / S&P ENGN unavailable / 12.46% |
| 2017-Q40/3 |
LoseENGN / S&P ENGN unavailable / 6.64% |
LoseENGN / S&P ENGN unavailable / 7.03% |
LoseENGN / S&P ENGN unavailable / 13.82% |
| 2017-Q30/3 |
LoseENGN / S&P ENGN unavailable / 4.48% |
LoseENGN / S&P ENGN unavailable / 5.68% |
LoseENGN / S&P ENGN unavailable / 17.57% |
| 2017-Q20/3 |
LoseENGN / S&P ENGN unavailable / 3.09% |
LoseENGN / S&P ENGN unavailable / 4.83% |
LoseENGN / S&P ENGN unavailable / 17.74% |
| 2017-Q10/3 |
LoseENGN / S&P ENGN unavailable / 6.07% |
LoseENGN / S&P ENGN unavailable / 3.67% |
LoseENGN / S&P ENGN unavailable / 13.32% |
| 2016-Q40/3 |
LoseENGN / S&P ENGN unavailable / 3.82% |
LoseENGN / S&P ENGN unavailable / 2.09% |
LoseENGN / S&P ENGN unavailable / 7.05% |
| 2016-Q30/3 |
LoseENGN / S&P ENGN unavailable / 3.85% |
LoseENGN / S&P ENGN unavailable / 0.20% |
LoseENGN / S&P ENGN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ENGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -58.66% | 20.78% |
| Annualized return | -58.66% | 20.78% |
5Y · 2022-02-01 to 2026-08-27
| Metric | ENGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -80.63% | 83.14% |
| Annualized return | -27.98% | 12.86% |
10Y · 2022-02-01 to 2026-08-27
| Metric | ENGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -80.63% | 319.30% |
| Annualized return | -15.14% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |